Literature DB >> 15592853

Incidence and survival of patients with Dukes' A (stages T1 and T2) colorectal carcinoma: a 15-year population-based study.

Carmela Di Gregorio1, Piero Benatti, Lorena Losi, Luca Roncucci, Giuseppina Rossi, Giovanni Ponti, Massimiliano Marino, Monica Pedroni, Alessandra Scarselli, Barbara Roncari, Maurizio Ponz de Leon.   

Abstract

BACKGROUND AND AIMS: Patients with stage I (Dukes' A) colorectal carcinoma tend to show a good prognosis; however, recurrences can be observed in some patients. Through a specialized colorectal cancer Registry, we attempted to investigate the epidemiological and clinical features of individuals with Dukes' A neoplasms. PATIENTS AND METHODS: From 1984 to 1998, 295 individuals were diagnosed with Stage I /Dukes' A tumors; 150 of these had lesions infiltrating the muscular wall (T2), while 145 had neoplasms limited to the submucosa (T1).
RESULTS: Dukes' A tumors represented 13.8% of all registered neoplasms; the percentage doubled over the study period (8.1% in the first year vs. 16.8% in the final year). In each year of observation, the preferential locations were the rectum and sigmoid colon (75% of all lesions). Most patients required surgery, but only 21.3% could be managed by endoscopic polypectomy. Overall 5-year survival was 81.0% (82.1% in T1, 80.0% in T2). Recurrences were seen in 6.8% (2.8% in T1, 10.7% in T2), while 36 patients (12.2%) died of causes unrelated to colorectal cancer. In 17 out of 20 patients who died of cancer, the lesions were localized in the rectosigmoid region. Survival analysis showed a significantly better prognosis (P<0.007) for patients with T1 tumors.
CONCLUSIONS: The proportion of stage I colorectal tumors tended to increase over time. Although the overall prognosis is good in four-fifths of the cases, approximately one-fifth of these patients die of recurrent disease or of other causes. As expected, the prognosis was significantly more favorable for patients with T1 lesions. For patients with T2 tumors, radical surgery is the most appropriate approach.

Entities:  

Mesh:

Year:  2004        PMID: 15592853     DOI: 10.1007/s00384-004-0665-6

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  34 in total

1.  Cancer statistics, 1999.

Authors:  S H Landis; T Murray; S Bolden; P A Wingo
Journal:  CA Cancer J Clin       Date:  1999 Jan-Feb       Impact factor: 508.702

2.  Survival after curative resection of lymph node negative colorectal carcinoma. A prospective study of 910 patients.

Authors:  R C Newland; O F Dent; P H Chapuis; L Bokey
Journal:  Cancer       Date:  1995-08-15       Impact factor: 6.860

Review 3.  Tumour suppressor genes in disease and therapy.

Authors:  G R Skuse; J W Ludlow
Journal:  Lancet       Date:  1995-04-08       Impact factor: 79.321

Review 4.  The role of gene-environment interaction in the aetiology of human cancer: examples from cancers of the large bowel, lung and breast.

Authors:  L A Mucci; S Wedren; R M Tamimi; D Trichopoulos; H O Adami
Journal:  J Intern Med       Date:  2001-06       Impact factor: 8.989

Review 5.  Molecular detection of micrometastases and circulating tumor cells in solid tumors.

Authors:  R A Ghossein; S Bhattacharya; J Rosai
Journal:  Clin Cancer Res       Date:  1999-08       Impact factor: 12.531

6.  Identification of hereditary nonpolyposis colorectal cancer in the general population. The 6-year experience of a population-based registry.

Authors:  M Ponz de Leon; R Sassatelli; P Benatti; L Roncucci
Journal:  Cancer       Date:  1993-06-01       Impact factor: 6.860

7.  Clinical and pathologic prognostic indicators in colorectal cancer. A population-based study.

Authors:  M Ponz de Leon; M Sant; A Micheli; C Sacchetti; C Di Gregorio; R Fante; G Zanghieri; G Melotti; G Gatta
Journal:  Cancer       Date:  1992-02-01       Impact factor: 6.860

8.  Late relapse and mortality in stage I large bowel cancer.

Authors:  G J Hill; B C Ghosh
Journal:  J Surg Oncol       Date:  1992-09       Impact factor: 3.454

9.  Patterns of recurrence following curative resection of adenocarcinoma of the colon and rectum.

Authors:  R M Olson; N P Perencevich; A W Malcolm; J T Chaffey; R E Wilson
Journal:  Cancer       Date:  1980-06-15       Impact factor: 6.860

10.  Colorectal cancer screening: clinical applications.

Authors:  Judith M E Walsh; Jonathan P Terdiman
Journal:  JAMA       Date:  2003-03-12       Impact factor: 56.272

View more
  10 in total

1.  Cost of care for colorectal cancer in Ireland: a health care payer perspective.

Authors:  L Tilson; L Sharp; C Usher; C Walsh; Whyte S; A O'Ceilleachair; C Stuart; B Mehigan; M John Kennedy; P Tappenden; J Chilcott; A Staines; H Comber; M Barry
Journal:  Eur J Health Econ       Date:  2011-06-03

2.  Stage I colorectal carcinoma: VEGF immunohistochemical expression, microvessel density, and their correlation with clinical outcome.

Authors:  Valeria Barresi; Carmela Di Gregorio; Luca Regiani-Bonetti; Maurizio Ponz-De Leon; Gaetano Barresi; Enrica Vitarelli
Journal:  Virchows Arch       Date:  2010-06-08       Impact factor: 4.064

3.  Neutrophil gelatinase-associated lipocalin immunoexpression in colorectal carcinoma: A stage-specific prognostic factor?

Authors:  Valeria Barresi; Roberta Lucianò; Enrica Vitarelli; Agata Labate; Giovanni Tuccari; Gaetano Barresi
Journal:  Oncol Lett       Date:  2010-09-23       Impact factor: 2.967

4.  Sleep fragmentation in mice induces nicotinamide adenine dinucleotide phosphate oxidase 2-dependent mobilization, proliferation, and differentiation of adipocyte progenitors in visceral white adipose tissue.

Authors:  Abdelnaby Khalyfa; Yang Wang; Shelley X Zhang; Zhuanhong Qiao; Amal Abdelkarim; David Gozal
Journal:  Sleep       Date:  2014-05-01       Impact factor: 5.849

Review 5.  Clinical outcome of low- and high-risk malignant colorectal polyps: results of a population-based study and meta-analysis of the available literature.

Authors:  Carmela Di Gregorio; Luca Reggiani Bonetti; Carmela de Gaetani; Monica Pedroni; Shaniko Kaleci; Maurizio Ponz de Leon
Journal:  Intern Emerg Med       Date:  2012-03-27       Impact factor: 3.397

6.  Serum cellular apoptosis susceptibility protein is a potential prognostic marker for metastatic colorectal cancer.

Authors:  Chin-Shaw Stella Tsai; Hung-Chang Chen; Jai-Nien Tung; Shung-Sheng Tsou; Tang-Yi Tsao; Ching-Fong Liao; Ying-Chun Chen; Chi-Yuan Yeh; Kun-Tu Yeh; Ming-Chung Jiang
Journal:  Am J Pathol       Date:  2010-02-11       Impact factor: 4.307

7.  The science and politics of colorectal cancer screening.

Authors:  Geir Hoff; Michael Bretthauer
Journal:  PLoS Med       Date:  2006-01-03       Impact factor: 11.069

8.  Cost-effectiveness of aspirin adjuvant therapy in early stage colorectal cancer in older patients.

Authors:  Swee Sung Soon; Whay-Kuang Chia; Mun-ling Sarah Chan; Gwo Fuang Ho; Xiao Jian; Yan Hong Deng; Chuen-Seng Tan; Atul Sharma; Eva Segelov; Shaesta Mehta; Raghib Ali; Han-Chong Toh; Hwee-Lin Wee
Journal:  PLoS One       Date:  2014-09-24       Impact factor: 3.240

9.  Management dilemma; a woman with cystic fibrosis and severe lung disease presenting with colonic carcinoma: a case report.

Authors:  Andrea N Lees; David W Reid
Journal:  J Med Case Rep       Date:  2008-12-15

10.  Prognostic value of microvascular density in dukes a and B (t1-t4, n0, m0) colorectal carcinomas.

Authors:  Rafael Uribarrena A; Javier Ortego; Javier Fuentes; Nuria Raventós; Pilar Parra; Rafael Uribarrena E
Journal:  Gastroenterol Res Pract       Date:  2009-11-04       Impact factor: 2.260

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.